Oropharyngeal candidiasis in head and neck cancer patients treated with radiation: Update 2011

Supportive Care in Cancer

Volumn 19, Issue 6, 2011, Pages 737-744

  Bensadoun, Rene Jean ^a   Patton, Lauren L ^b   Lalla, Rajesh V ^c   Epstein, Joel B ^d  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Head and neck cancer; Oropharyngeal candidiasis; Radiotherapy

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; CLOTRIMAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LORAMYC; MICAFUNGIN; MICONAZOLE; NYSTATIN; ORAVIG; POLYENE; POSACONAZOLE; SUCROSE; UNCLASSIFIED DRUG; VORICONAZOLE; ANTIFUNGAL AGENT;

CANCER PATIENT; CANCER RADIOTHERAPY; CANDIDA; CANDIDIASIS; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; LOADING DRUG DOSE; LOCAL THERAPY; MOUTH HYGIENE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SYSTEMIC THERAPY; THRUSH; TOOTH DISEASE; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; HEAD AND NECK TUMOR; HETEROZYGOTE; ISOLATION AND PURIFICATION; MICROBIOLOGY; PHARYNX DISEASE; RISK FACTOR;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, ORAL; CARRIER STATE; HEAD AND NECK NEOPLASMS; HUMANS; PHARYNGEAL DISEASES; RISK FACTORS;

EID: 80051656501     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1154-4     Document Type: Review

References (48)

1. Al-Attas SA, Amro SO (2010) Candidal colonization, strain diversity, and antifungal susceptibility among adult diabetic patients. Ann Saudi Med 30:101-108
2. Barchiesi F, Maracci M, Radi B, Arzeni D, Baldassarri I, Giacometti A, Scalise G (2002) Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother 50:999-1002 (Pubitemid 36032823)
3. Belazi M, Velegraki A, Koussidou-Eremondi T, Andreadis D, Hini S, Arsenis G, Eliopoulou C, Destouni E, Antoniades D (2004) Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment. Oral Microbiol Immunol 19:347-351 (Pubitemid 39487667)
4. Bensadoun RJ, Daoud D, Bastit L, El Gueddari B, Allavena C, Benidder A, Gourmet R (2008) Comparison of the efficacy and safety of miconazole Lauriad® tablets to those of miconazole gel in the treatment of oropharyngeal candidiasis: a controlled multicenter, randomised, phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer 112:204-211
5. Bensadoun RJ, Franquin JC, Ciais G, Darcourt V, Schubert MM, Viot M, Dejou J, Tardieu C, Benezery K, Nguyen TD, Laudoyer Y, Dassonville O, Poissonnet G, Vallicioni J, Thyss A, Hamdi M, Chauvel P, Demard F (1999) Low energy He/Ne laser in the prevention of radiation-induced mucositis: a multicenter phase III randomized study for patients with head and neck cancer. Support Care Cancer 7:244-252 (Pubitemid 29302632)
6. Bensadoun RJ, Magné N, Marcy PY, Demard F (2001) Chemotherapy-and radiotherapy-induced mucositis in head and neck cancer patients: new trends in pathophysiology, prevention and treatment. Eur Arch Otorhinolaryngol 258:481-487 (Pubitemid 33141265)
7. Charlier C, Hart E, Lefort A, Ribaud P, Dromer F, Denning DW, Lortholary O (2006) Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 57:384-410 (Pubitemid 43240191)
8. Clarkson JE, Worthington HV, Eden OB (2007) Interventions for preventing oral candidiasis for patients with cancer receiving treatment. Cochrane Database Syst Rev (1):CD003807
9. Coleman D, Sullivan D, Harrington B, Haynes K, Henman M, Shanley D, Shanley D, Bennett D, Moran G, McCreary C, O'Neill L (1997) Molecular and phenotypic analysis of Candida dubliniensis: a recently identified species linked with oral candidosis in HIV-infected and AIDS patients. Oral Dis 3:96-101
10. Corvo R, Amichetti M, Ascarelli A, Arcangeli G, Buffoli A, Cellini N, Cionini L, De Renzis C, Emiliani E, Franchini P, Gabriele P, Gobitti C, Grillo Ruggieri F, Bertoni F, Magrini SM, Marmiroli L, Orsatti M, Panizza GM, Tordiglione M, Ziccarelli L, Gava A, Zorat PL, Ghelfi R, Serra GF, Vitale V (2008) Effects of fluconazole in the prophylaxis of oropharyngeal candidiasis in patients undergoing radiotherapy for head and neck tumour: results from a double-blind placebo-controlled trial. Eur J Cancer Care 17:270-277
11. Dahiya MC, Redding SW, Dahiya RS, Eng TY, Kirkpatrick WR, Coco BJ, Sadkowski LC, Fothergill AW, Waite A, Rinaldi MG, Patterson TF, Thomas CR (2003) Oropharyngeal candidiasis caused by non-albicans yeast in patients receiving external beam radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 1:79-83 (Pubitemid 36959741)
12. Davies AN, Brailsford S, Broadley K, Beighton D (2002) Oral yeast carriage in patients with advanced cancer. Oral Microbiol Immunol 17:79-84
13. Davies AN, Brailsford SR, Beighton D (2006) Oral candidosis in patients with advanced cancer. Oral Oncol 42:698-702 (Pubitemid 44094236)
14. De Repentigny L, Lewandowski D, Jolicoeur P (2004) Immuno-pathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Rev 17:729-759 (Pubitemid 39372514)
15. Dupont B (2005) A prospective non comparative study evaluating tolerance and efficacy of miconazole muco-adhesive tablet (Loramyc*) for oral candidiasis in HIV patients. Clinical overview/study BA2002/01/03 (Dossier d'AMM, Miconazole Lauriad*, Sept.)
16. Ellepola AN, Samaranayake LP (2001) Adjunctive use of chlorhexidine in oral candidoses: a review. Oral Dis 7:11-17 (Pubitemid 32216851)
17. Epstein JB, Freilich MM, Le ND (1993) Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol 76:169-174 (Pubitemid 23262574)
18. Epstein JB, Gorsky M, Caldwell J (2002) Fluconazole mouth-rinses for oral candidiasis in postirradiation, transplant, and other patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93:671-675 (Pubitemid 41124624)
19. Finlay PM, Richardson MD, Robertson AG (1996) A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours. Br J Oral Maxillofac Surg 34:23-25 (Pubitemid 26067428)
20. Havlir DV, Dube MP, McCutchan JA, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Kumar PN, White AC Jr, Witt MD, Nightingale SD, Sepkowitz KA, MacGregor RR, Cheeseman SH, Torriani FJ, Zelasky MT, Sattler FR, Bozzette SA (1998) Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis 27:1369-1375 (Pubitemid 29242405)
21. Jham BC, Franca EC, Oliveira RR, Santos VR, Kowalski LP, da Silva Freire AR (2007) Candida oral colonization and infection in Brazilian patients undergoing head and neck radiotherapy: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103:355-358
22. Jham BC, Reis PM, Miranda EL, Lopes RC, Carvalho AL, Scheper MA, Freire AR (2008) Oral health status of 207 head and neck cancer patients before, during and after radiotherapy. Clin Oral Investig 12:19-24
23. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, Mcguire DB, Hutchins R, Peterson DE, Michelet M, Avritcher E, Jones J, Anthony L, Bowen J, Garden A, Hewson I, Spijkervet F, Logan R, Von Bültzingslöwen I, Brennan M, Stringer A, Barasch A, Damato K, Elad S, Altman A, Oberle-Edwards L, Johnson J, Wienandts P, Correa E, Bensadoun R-J, Lalla RV (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 169:820-831 (Pubitemid 46335677)
24. Kinirons MJ, Fleming P, Boyd D (1995) Dental caries experience of children in remission from acute lymphoblastic leukaemia in relation to the duration of treatment and the period of time in remission. Int J Paediatr Dent 5:169-172
25. Lalla RV, Latortue MC, Hong CH, Ariyawardana A, D'Amato-Palumbo S, Fischer DJ, Martof A, Nicolatou-Galitis O, Patton LL, Elting LS, Spijkervet FKL, Brennan MT (2010) A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer 18:985-992
26. Lalla RV, Sonis ST, Peterson DE (2008) Management of oral mucositis in patients who have cancer. Dent Clin North Am 52:61-67
27. Lass-Florl C, Gunsilius E, Gastl G, Englisch M, Koch G, Ulmer H, Dierich MP, Petzer A (2003) Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution. Ann Hematol 82:565-569 (Pubitemid 37220674)
28. Mann PA, McNicholas PM, Chau AS, Patel R, Mendrick C, Ullmann AJ, Cornely OA, Patino H, Black TA (2009) Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother 53:5026-5034
29. Nicolatou-Galitis O, Velegraki A, Sotiropoulou-Lontou A, Dardoufas K, Kouloulias V, Kyprianou K, Kolitsi G, Skarleas C, Pissakas G, Papanicolaou VS, Kouvaris J (2006) Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy. Support Care Cancer 14:44-51 (Pubitemid 43119596)
30. Pagani JL, Chave JP, Casjka C, Glauser MP, Bille J (2002) Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial. J Antimicrob Chemother 50:231-240 (Pubitemid 34918853)
31. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg B-J, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 1:503-535
32. Peterson DE (2006) New strategies for management of oral mucositis in cancer patients. J Supportive Oncol 4:9-13
33. Peterson DE, Bensadoun R-J, Roila F (2008) Management of oral and gastrointestinal mucositis: ESMO Clinical Recommendations. Ann Oncol 19(Suppl 2):122-125
34. Phillips SM, Dellinger TM (2005) Dental decay due to xerostomia and nystatin. Ann Pharmacother 39:1758 (Pubitemid 41393142)
35. Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G (1993) Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. J Antimicrob Chemother 31:973-984 (Pubitemid 23218159)
36. Ramirez-Amador V, Silverman S Jr, Mayre P, Tyler M, Quivey J (1997) Candidal colonization and oral candidiasis in patients undergoing oral and pharyngeal radiation therapy. Oral Surg Oral Med Oral Oral Pathol Oral Radiol Endod 84:149-153 (Pubitemid 127671954)
37. Redding SW, Dahiya MC, Kirkpatrick WR, Coco BJ, Patterson TF, Fothergill AW, Rinaldi MG, Thomas CR (2004) Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97:47-52 (Pubitemid 38064262)
38. Redding SW, Kirkpatrick WR, Coco BJ, Sadkowski L, Fothergill AW, Rinaldi MG, Eng TY, Patterson TF (2002) Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer. J Clin Microbiol 40:1879-1881 (Pubitemid 34493182)
39. Redding SW, Zellars RC, Kirkpatrick WR, McAtee RK, Caceres MA, Fothergill AW, Lopez-Ribot JL, Bailey CW, Rinaldi MG, Patterson TF (1999) Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol 37:3896-3900
40. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL (1997) Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on antifungal susceptibility testing of the national committee for clinical laboratory standards. Clin Infect Dis 24:235-247 (Pubitemid 127774263)
41. Ruhnke M (2006) Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts. Curr Drug Targets 7:495-504 (Pubitemid 43744840)
42. Scully C, el-Kabir M, Samaranayake LP (1994) Candida and oral candidosis: a review. Crit Rev Oral Biol Med 5:125-157 (Pubitemid 24380974)
43. Soysa NS, Ellepola AN (2005) The impact of cigarette/tobacco smoking on oral candidosis: an overview. Oral Dis 11:268-273 (Pubitemid 41725936)
44. Soysa NS, Samaranayake LP, Ellepola AN (2004) Cytotoxic drugs, radiotherapy and oral candidiasis. Oral Oncol 40:971-978 (Pubitemid 39422781)
45. Sweeney MP, Bagg J, Baxter WP, Aitchison TC (1998) Oral disease in terminally ill cancer patients with xerostomia. Oral Oncol 34:123-126 (Pubitemid 28207012)
46. World Health Organization (1979) Handbook for reporting results of cancer treatment. World Health Organization, Geneva, pp 15-22
47. Worthington HV, Clarkson JE, Eden OB (2007) Interventions for treating oral candidiasis for patients with cancer receiving treatment. Cochrane Database Syst Rev (2):CD001972
48. Zadik Y, Burnstein S, Derazne E, Sandler V, Ianculovici C, Halperin T (2010) Colonization of Candida: prevalence among tongue-pierced and non-pierced immunocompetent adults. Oral Dis 16:172-175